Laboratory study of NY-198 and clinical evaluation in respiratory tract infections

Seiichi Aonuma, Yutaka Tokue, Naoto Kitamura, Yoshihiro Honda, Reiko Ono, Akira Watanabe, Kohtaro Ohizumi, Kiyoshi Konno, Kohsaku Nagai

    Research output: Contribution to journalArticlepeer-review

    1 Citation (Scopus)


    We examined the in vitro antimicrobial activity of NY-198, a newly developed quinolone derivative by the broth-dilution method using an MIC-2000 system, and compared minimum inhibitory concentrations (MICs) of NY-198 against 170 clinical isolates with those of norfloxacin (NFLX), ofloxacin (OFLX) and ciprofloxacin (CPFX). Against S. aureus, NY-198 was less active than CPFX and OFLX but more active than NFLX. However, against all other isolates tested (E. colt, K. pneumoniae, S. marcescens, E. cloacae, P. mirabilis, M. morganii, P. vulgaris and P. aeruginosa) NY-198 was less active than CPFX and NFLX, and nearly as active as OFLX. Thirty-four patients suffering from respiratory tract infection received orally 400 or 600 mg of NY-198 a day. Clinical response was excellent in 2, good in 19, fair in 4, and poor in 8; 1 was not evaluated. Dizziness was observed in two and anorexia with fatiguability in one patient. No abnormalities in laboratory findings were observed.

    Original languageEnglish
    Pages (from-to)486-494
    Number of pages9
    Publication statusPublished - 1988 Jan 1

    ASJC Scopus subject areas

    • Pharmacology (medical)
    • Infectious Diseases
    • Pharmacology
    • Drug Discovery
    • Oncology


    Dive into the research topics of 'Laboratory study of NY-198 and clinical evaluation in respiratory tract infections'. Together they form a unique fingerprint.

    Cite this